Form 8-K - Current report:
SEC Accession No. 0001193125-26-168569
Filing Date
2026-04-22
Accepted
2026-04-22 08:13:57
Documents
15
Period of Report
2026-04-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sabs-20260422.htm   iXBRL 8-K 51337
2 EX-99.1 sabs-ex99_1.htm EX-99.1 36675
3 EX-99.2 sabs-ex99_2.htm EX-99.2 1108
4 GRAPHIC img1871078_0.jpg GRAPHIC 35521
5 GRAPHIC img1871078_1.gif GRAPHIC 25996
6 GRAPHIC img1871078_2.gif GRAPHIC 38708
7 PDF COURTESY COPY sabs-ex99_2.pdf EX-99.2 4092117
  Complete submission text file 0001193125-26-168569.txt   6011340

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20260422.xsd EX-101.SCH 47021
18 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20260422_htm.xml XML 6609
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39871 | Film No.: 26881349
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)